These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 24724258)

  • 21. Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials.
    Felker GM; Hasselblad V; Hernandez AF; O'Connor CM
    Am Heart J; 2009 Sep; 158(3):422-30. PubMed ID: 19699866
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New therapies for heart failure.
    Riggs JM
    RN; 2004 Mar; 67(3):28-32; quiz 33. PubMed ID: 15065491
    [No Abstract]   [Full Text] [Related]  

  • 23. [Selective aldosterone blocking in heart failure. Eplerenone reduces the risk after infarction].
    MMW Fortschr Med; 2003 Oct; 145(44):42-3. PubMed ID: 14655506
    [No Abstract]   [Full Text] [Related]  

  • 24. Paediatric heart failure trials...and tribulations.
    Shaddy RE
    Cardiol Young; 2007 Aug; 17(4):354-5. PubMed ID: 17572938
    [No Abstract]   [Full Text] [Related]  

  • 25. [Therapy of heart failure after myocardial infarction. With eplerenone a new course].
    MMW Fortschr Med; 2004 Oct; 146(43):58-9. PubMed ID: 15559524
    [No Abstract]   [Full Text] [Related]  

  • 26. Spironolactone for heart failure.
    Med Lett Drugs Ther; 1999 Sep; 41(1061):81-2. PubMed ID: 10505071
    [No Abstract]   [Full Text] [Related]  

  • 27. Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study.
    Eurlings LW; van Pol PE; Kok WE; van Wijk S; Lodewijks-van der Bolt C; Balk AH; Lok DJ; Crijns HJ; van Kraaij DJ; de Jonge N; Meeder JG; Prins M; Pinto YM
    J Am Coll Cardiol; 2010 Dec; 56(25):2090-100. PubMed ID: 21144969
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Response to "Getting the right message".
    Januzzi JL; Camargo CA; Tung R
    Ann Emerg Med; 2007 Mar; 49(3):381-3; discussion 383; author reply 384. PubMed ID: 17317512
    [No Abstract]   [Full Text] [Related]  

  • 29. Brain natriuretic peptide is unchanged after 4 weeks of continuous positive airway pressure therapy.
    Pepperell J; Stradling J; Davies R
    J Sleep Res; 2006 Dec; 15(4):463-4. PubMed ID: 17118104
    [No Abstract]   [Full Text] [Related]  

  • 30. Absolute, not relative, changes are important when interpreting trial data.
    Kalra PR; Sharma R
    J Am Coll Cardiol; 2001 Dec; 38(7):2132-3. PubMed ID: 11738326
    [No Abstract]   [Full Text] [Related]  

  • 31. Natriuretic peptides in patients with atrial fibrillation and advanced chronic heart failure: determinants and prognostic value of (NT-)ANP and (NT-pro) BNP.
    Shelton RJ; Goode K; Cleland JG
    Europace; 2007 Feb; 9(2):147; author reply 148. PubMed ID: 17227813
    [No Abstract]   [Full Text] [Related]  

  • 32. Prognostic value of plasma renin activity in heart failure.
    Vergaro G; Emdin M; Iervasi A; Zyw L; Gabutti A; Poletti R; Mammini C; Giannoni A; Fontana M; Passino C
    Am J Cardiol; 2011 Jul; 108(2):246-51. PubMed ID: 21545993
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical factors affecting serum potassium concentration in cardio-renal decompensation syndrome.
    Ueno H; Yoshimura M; Nakayama M; Yamamuro M; Nishijima T; Kusuhara K; Nagayoshi Y; Kojima S; Kaikita K; Sumida H; Sugiyama S; Ogawa H
    Int J Cardiol; 2010 Jan; 138(2):174-81. PubMed ID: 18804879
    [TBL] [Abstract][Full Text] [Related]  

  • 34. N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial.
    Lainchbury JG; Troughton RW; Strangman KM; Frampton CM; Pilbrow A; Yandle TG; Hamid AK; Nicholls MG; Richards AM
    J Am Coll Cardiol; 2009 Dec; 55(1):53-60. PubMed ID: 20117364
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High prevalence of microalbuminuria in chronic heart failure patients.
    van de Wal RM; Asselbergs FW; Plokker HW; Smilde TD; Lok D; van Veldhuisen DJ; van Gilst WH; Voors AA
    J Card Fail; 2005 Oct; 11(8):602-6. PubMed ID: 16230263
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Q: Should target natriuretic peptide levels be used for outpatient management of chronic heart failure?
    Ibrahim A; Baibars M; Alraies MC; Oliveira GH
    Cleve Clin J Med; 2012 Jan; 79(1):22-5. PubMed ID: 22219230
    [No Abstract]   [Full Text] [Related]  

  • 37. Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure.
    Tamirisa KP; Aaronson KD; Koelling TM
    Am Heart J; 2004 Dec; 148(6):971-8. PubMed ID: 15632880
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Spironolactone in the management of congestive cardiac failure: a review.
    Muller J
    Clin Ther; 1986; 9(1):63-76. PubMed ID: 2880664
    [No Abstract]   [Full Text] [Related]  

  • 39. Spironolactone in left-sided heart failure: how does it fit in?
    Margo KL; Luttermoser G; Shaughnessy AF
    Am Fam Physician; 2001 Oct; 64(8):1393-8. PubMed ID: 11681781
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The EMPHASIS-HF study].
    Boccanelli A; Agostoni P
    G Ital Cardiol (Rome); 2011 May; 12(5):315-8. PubMed ID: 21593949
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.